Key Information
New guidelines empower clinicians with practical diagnostic framework
The systemic disorder AL amyloidosis (light chain amyloidosis) is highly treatable when detected early, yet it often takes patients upwards of two years to receive a diagnosis. To address this challenge, the American Society of Hematology (ASH) convened a panel of experts to develop guidelinesexternal link, opens in a new tab that foster prompt diagnosis of this life-threatening disease.
Background
AL amyloidosis is a protein misfolding disorder that starts with the presence of abnormal plasma cells in the bone marrow. The disease may mimic other conditions given its systemic nature and often nonspecific symptoms. By the time patients are diagnosed, they often have irreversible organ damage.